The prescribing information for metformin ER tablets states the tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It also gives a starting dose, a weekly step-up and a maximum. This guide repeats that wording and does not turn it into dosing advice, because a licensed provider decides what applies to a patient. The sections below cover the indication, the dosing wording, kidney checks and the side effects the label lists.
What the label says the tablets are for
The indication statement has three parts: the population (adults), the condition (type 2 diabetes mellitus) and the role (an adjunct to diet and exercise, with the stated aim of improving glycemic control). In this wording, "adjunct" places the tablets alongside diet and exercise. For pediatric patients, the label states that safety and effectiveness of the extended-release tablets have not been established.
The label also states that there have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with the tablets. That sentence appears in this prescribing information and in the warnings section of a second prescribing information document for metformin ER tablets.
Dosing facts in the label
The table lists what the label says. It does not say what any person should take.
| Question | What the source says |
|---|---|
| Starting dose | The label gives the recommended starting dose as 500 mg orally once daily with the evening meal. |
| Increases | The label says to increase the dose in increments of 500 mg weekly on the basis of glycemic control and tolerability. |
| Maximum | The same label sentence gives a maximum of 2,000 mg once daily with the evening meal. |
| How to take the tablet | The label instructs patients to swallow the extended-release tablets whole and never crush, cut or chew them. |
The starting dose and the maximum are both worded as once daily with the evening meal. The increase is tied to two things the label names: glycemic control and tolerability.
Kidney checks the label describes
The label says to assess renal function prior to initiation of the tablets and periodically thereafter. The warnings section of a second prescribing information document says to obtain an eGFR at least annually in all patients taking the tablets. The first covers the time before the tablets are started and the time afterward. The second names a minimum frequency for eGFR, at least annually. Both statements are about checking kidney function, not about the result of any check.
Side effects the label lists
The highlights of the prescribing information state that the most common adverse reactions (> 5.0%) are diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache.
The adverse reactions section states that diarrhea led to discontinuation of the tablets in 0.6% of patients. The same section also lists abdominal pain, constipation, distention abdomen, dyspepsia/heartburn, flatulence, dizziness, headache, upper respiratory infection, and taste disturbance as more commonly reported with the tablets than placebo. The two lists are described differently, and flatulence and headache appear on both.
What this does not tell you
These are statements from two prescribing information documents for metformin ER tablets, not a recommendation for anyone. The dosing, pediatric and renal assessment statements come from the first, and the annual eGFR and side effect statements from the second. The starting dose, weekly step-up and maximum are shown as written. They do not say which dose suits a particular person, and a licensed provider decides how they apply to a patient. The macrovascular sentence says what studies have not established. It does not say that the tablets have or lack any such effect. The side effect lists show what the label reports and do not give any one person's chance of a side effect. This guide does not rank them or call any of them mild. It also does not cover the boxed warning, drug interactions, kidney function limits or trial results.